SEC Form 5 · accession 0001628280-26-046511
TriSalus Life Sciences, Inc. · TLSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary T Szela
Officer — CEO and President · Director
Period of report
Dec 31, 2025
Accepted (ET)
Jul 1, 2026 · 4:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001826667
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 31, 2024 | A | 3,530 | $4.26 | A | 513,207 | D | |
| Common StockF1 | Jun 30, 2025 | A | 2,848 | $4.23 | A | 596,726 | D | |
| Common StockF1 | Dec 31, 2025 | A | 2,100 | $4.38 | A | 1,023,826 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.